Empatica Receives New FDA Clearance for Its Health Monitoring Platform and Announces Series B Financing

Empatica, a digital health and AI company which develops medical-grade wearables and algorithms for health monitoring and diagnostics, has announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration (FDA).

The company also announced the recent closing of its Series B financing, led by Sanofi Ventures and RA Capital Management, and participation by Black Opal Ventures. The investment will enable Empatica to expand its suite of digital biomarkers, for use in patient care and as digital endpoints in clinical trials.

As per the company report, the Empatica Health Monitoring Platform is a ‘full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wearable. In addition, the Platform includes Empatica's proprietary Care software suite, secure cloud infrastructure, and clinically validated digital biomarkers.’

Empatica's Platform has been cleared for continuous data collection to monitor blood oxygen saturation (SpO2) during rest, peripheral skin temperature, activity associated with movement during sleep, and Electrodermal Activity (EDA). Each of Empatica's digital biomarkers is based on trained algorithms that analyze sensor data in one-minute intervals, and have been rigorously validated in clinical studies conducted with diverse groups of participants. 

Platform users can also access raw data collected by EmbracePlus' five sensors, and research-grade digital biomarkers such as Pulse Rate, Pulse Rate Variability, and Respiratory Rate.

The Empatica Health Monitoring Platform is being used globally by major pharmaceutical companies to continuously gather and analyze physiological data for clinical trials evaluating the impact of novel therapeutics, with Empatica collaborating to develop digital biomarkers for use as endpoints. Researchers also have the possibility to develop their own digital biomarkers, which they can implement in their digital health applications or infrastructure using the Platform's Software Development Kit.

Join our Masterclass on ‘The New Reimbursement Pathway in France’ on 30th November. Click here to Request to Join.